PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

被引：3
|
作者：
Raben, D. [1 ]
Faivre-Finn, C. [2 ]
Spigel, D. [3 ]
Daniel, D. [3 ,4 ]
Villegas, A. [5 ]
Vincente, D. [6 ]
Hui, R. [7 ,8 ]
Carpeno, J. de Castro [9 ]
Murakami, S. [10 ]
Paz-Ares, L. [11 ,12 ]
Ozguroglu, M. [13 ]
Kurata, T. [14 ]
Chiappori, A. [15 ]
Lee, K. H. [16 ]
de Wit, M. [17 ]
Poole, L. [18 ]
Wadsworth, C. [19 ]
Dennis, P. A. [20 ]
Antonia, S. J. [15 ]
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Manchester, Div Canc Sci, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Chattanooga, TN USA
[5] Canc Specialists North Florida, Jacksonville, FL USA
[6] Hosp Univ Virgen Macarena, Seville, Spain
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Univ Sydney, Sydney, NSW, Australia
[9] Hosp Univ La Paz, Madrid, Spain
[10] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[11] Univ Complutense, Hosp Univ Octubre 12, CiberOnc, Madrid, Spain
[12] CNIO, Madrid, Spain
[13] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Istanbul, Turkey
[14] Kansai Med Univ Hosp, Hirakata, Osaka, Japan
[15] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[16] Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Cheongju, South Korea
[17] Vivantes Klinikum Neukoelln, Berlin, Germany
[18] AstraZeneca, Cambridge, England
[19] AstraZeneca, Alderley Pk, England
[20] AstraZeneca, Gaithersburg, MD USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 05期
关键词：
D O I：
10.1016/j.ijrobp.2018.08.057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA10
引用
收藏
页码：1607 / 1608
页数：2
相关论文
共 50 条
  • [41] Pathological response after neoadjuvant chemotherapy versus chemoradiotherapy in stage III NSCLC
    Munoz Guglielmetti, D.
    Sanchez, D.
    Reyes, R.
    Boada, M.
    Mases, J.
    Molla, M.
    Casas, F.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S981 - S983
  • [42] PACIFIC-6: A Phase II Study of Durvalumab Following Sequential Chemoradiotherapy in Patients with Stage III, Unresectable NSCLC
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Reck, M.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S403 - S404
  • [43] Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
    Garassino, M. C.
    Mazieres, J.
    Reck, M.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L. S.
    Mansy, T.
    Cortinovis, D. L.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. Garcia
    Velarde, L. E. Chara
    Caro, R. Bernabe
    Paz-Ares, L.
    Chander, P.
    Perez, I. Diaz
    Foroutanpour, K.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1301 - S1302
  • [44] Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
    Naidoo, Jarushka
    Antonia, Scott
    Wu, Yi-Long
    Cho, Byoung Chul
    Thiyagarajah, Piruntha
    Mann, Helen
    Newton, Michael
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 657 - 663
  • [45] A retrospective analysis of risk factors for Durvalumab related interstitial lung disease after chemoradiotherapy in Stage III NSCLC
    Hirama, Nobuyuki
    Yamamoto, Masaki
    Kanaoka, Hiromi
    Muraoka, Tatuya
    Somekawa, Kouhei
    Hirata, Momo
    Kamimaki, Tisato
    Ikeda, Syuuhei
    Kubo, Sousuke
    Ryouta, Usio
    Manabe, Saki
    Kudou, Makoto
    Kaneko, Takesi
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [46] Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
    Cortiula, Francesco
    De Ruysscher, Dirk
    Steens, Michelle
    Wijsman, Robin
    van der Wekken, Anthonie
    Alberti, Martina
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 172 - 178
  • [47] Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
    Huang, Y.
    Zhao, J.
    Soon, Y. Y.
    Wong, A.
    Ang, Y.
    Asokumaran, Y.
    Low, J. L.
    Lee, M.
    Choo, J.
    Chan, G.
    Kee, A.
    Tay, S. H.
    Goh, B. C.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1044 - S1044
  • [48] First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC
    Faehling, Martin
    Planchard, David
    Cho, Byoung Chul
    Gray, Jhanelle Elaine
    Paz-Ares, Luis G.
    Ozguroglu, Mustafa
    Villegas, Augusto E.
    Daniels, Davey B.
    Vicente, David
    Murakami, Shuji
    Hui, Rina
    Kurata, Takayasu
    Chiappori, Alberto
    Lee, Ki Hyeong
    Gu, Yu
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott Joseph
    de Wit, Maike
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 120 - 120
  • [49] Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
    Vansteenkiste, J. F.
    Naidoo, J.
    Faivre-Finn, C.
    Ozguroglu, M.
    Villegas, A.
    Daniel, D.
    Murakami, S.
    Hui, R.
    Lee, K. H.
    Cho, B. C.
    Kubota, K.
    Taboada, M.
    Wadsworth, C.
    Dennis, P. A.
    Antonia, S. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 592 - +
  • [50] Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
    Ozguroglu, M.
    Levy, B.
    Horinouchi, H.
    Yu, J.
    Grainger, E.
    Phuong, P.
    Peterson, D. A.
    Newton, M.
    Spira, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S991 - S991
12345